77 papers
Pharmacology and toxicology explore how substances interact with living systems, ranging from the development of life-saving medicines to understanding the dangers of chemical exposure. This field sits at the critical intersection of chemistry and biology, asking essential questions about how drugs work, how the body processes them, and what happens when things go wrong. It is a dynamic area where researchers constantly strive to improve patient safety while discovering new therapeutic possibilities.
At Gist.Science, we bridge the gap between complex research and public understanding by curating the latest preprints from bioRxiv in this vital category. Our team processes every new submission from bioRxiv as it appears, transforming dense scientific data into both plain-language overviews and detailed technical summaries. This ensures that whether you are a specialist or a curious reader, you can grasp the significance of these emerging findings without getting lost in jargon.
Below are the most recent pharmacology and toxicology papers from bioRxiv, each accompanied by our expert analysis to help you navigate the latest scientific breakthroughs.
This study demonstrates that targeting Protease-activated Receptor 4 (PAR4) with the antagonist VU6073819 significantly mitigates kidney injury, inflammation, and mortality in a mouse model of ischemia-reperfusion-induced acute kidney injury, establishing PAR4 as a promising therapeutic target.
This study demonstrates that conventional reference genes are unstable during fish oogenesis and proposes a more robust normalization framework using multiple reference genes and total cDNA concentration to ensure accurate and reproducible transcriptomic analysis in fish ovaries.
This study demonstrates that intravenous administration of the metalloproteinase inhibitor Marimastat, either alone or combined with a phospholipase A2 inhibitor, significantly improves skeletal muscle regeneration and reduces fibrosis in mice even when given 24 hours after Bothrops asper venom-induced myonecrosis.
This study demonstrates that incorporating literature-derived priors into Bayesian hierarchical modeling enables a more robust and physiologically consistent population pharmacokinetic characterization of ceftolozane-tazobactam in critically ill patients with small sample sizes, overcoming the limitations of traditional nonlinear mixed-effects modeling to better optimize dosing strategies.
This preclinical study demonstrates that administering Ifosfamide at 13 Hours After Light Onset (HALO) in mice significantly minimizes multi-organ toxicity, including encephalopathy, by aligning treatment with the drug's circadian tolerance peak.
This study demonstrates that the ethanolic extract of *Asparagus racemosus* exhibits significant antidiabetic potential by inhibiting carbohydrate digestion and absorption, enhancing glucose uptake, and displaying antioxidant activity, likely due to its rich content of phytochemicals such as flavonoids and saponins.
This study demonstrates that microcystin-LR accumulates in human placental trophoblasts via OATP4A1-mediated transport, a process significantly enhanced by both hypoxic conditions and trophoblast cell fusion.
This study demonstrates that an integrated evaluation framework combining structural, functional, and cellular immunotoxicity endpoints in rats effectively characterizes immune system perturbation by showing concordant evidence of lymphoid depletion, impaired adaptive immune responses, and specific lymphocyte subset reductions induced by a reference immunosuppressive compound.
This study demonstrates that aerosolized nanoalgosomes derived from the marine microalga *Tetraselmis chuii* are non-cytotoxic, preserve epithelial barrier integrity, and effectively mitigate oxidative stress and inflammation in bronchial epithelial-macrophage co-cultures, highlighting their potential as a safe and sustainable therapeutic strategy for chronic inflammatory lung diseases.
This study demonstrates that the ROCK inhibitor fasudil exhibits beneficial anti-inflammatory and pro-proliferative effects on human trisomy 21 neural progenitor cells, suggesting its potential as a candidate prenatal pharmacotherapy for Down syndrome.